tiprankstipranks
Trending News
More News >

Orthocell Secures FDA Clearance for Remplir™, Eyes US Market Expansion

Story Highlights
Orthocell Secures FDA Clearance for Remplir™, Eyes US Market Expansion

Confident Investing Starts Here:

Orthocell Ltd ( (AU:OCC) ) has issued an announcement.

Orthocell Limited has achieved a significant milestone with the US FDA 510(k) clearance for its nerve repair product, Remplir™, positioning the company to enter the lucrative US$1.6 billion nerve repair market. This clearance is expected to drive a substantial increase in revenue as the company has prepared logistics and sales pathways for its US launch. Additionally, Orthocell reported strong quarterly revenue growth, maintaining a robust cash position, and is expanding its market reach with regulatory applications in Canada and Thailand. The company’s inclusion in the S&P/ASX All Ordinaries Index further underscores its growing market presence.

More about Orthocell Ltd

Orthocell Limited is a regenerative medicine company specializing in innovative products for nerve repair and dental guided bone regeneration. The company focuses on the global market, particularly the US, with its flagship products Remplir™ and Striate+™.

YTD Price Performance: 4.80%

Average Trading Volume: 1,559,039

Technical Sentiment Signal: Strong Sell

Current Market Cap: A$343.6M

See more insights into OCC stock on TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1